A comparative study of the therapeutic effect of topical finasteride with oral finasteride in patients with androgenetic alopecia .
Phase 3
Recruiting
- Conditions
- Androgenic alopecia.Androgenic alopecia
- Registration Number
- IRCT20220901055844N1
- Lead Sponsor
- Shiraz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 28
Inclusion Criteria
Having androgenic alopecia grade 2 to 5 based on the Norwood Hamilton classification in men
Age above 18 years
Not receiving treatment for androgenic alopecia during the last 3 months
Having androgenetic alopecia grade 2 to 3 according to Ludwig grading in women
Menopausal women or women over 18 years of age who use IUD or TL.
Informed consent to participate in the study
Exclusion Criteria
Failure to sign the consent form.
History of allergic reaction and anaphylaxis to Finasteride drug
Pregnancy or trying to have a child.
Individual history of infertility
Active infection or any scratches and wounds in the scalp
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The rate of improvement in hair growth. Timepoint: evaluating the improvement of hair loss at the beginning of the study and at the end of 3months and at the end of 6months. Method of measurement: Comparison of the effect of topical finasteride with oral finasteride in the treatment of androgenic hair loss. how to measure this variable is with a questionnaire.;Serum Dihydrotestosterone. Timepoint: At the beginning of the study and at the end of 6 months. Method of measurement: by free blood sampling from the patient at the Motahari clinic in Shiraz byuse a lab kit to measure blood Dihydrotestosterone.;Investigation of drug side effects. Timepoint: At the end of the 3rd month and the end of the 6th month. Method of measurement: At each stage, unwanted side effects, including redness, itching and symptoms of drug reaction, as well as breast tenderness, and symptoms of sexual dysfunction, are asked from the patients and recorded in the questionnaire.
- Secondary Outcome Measures
Name Time Method